search
Back to results

A Randomized, Controlled, Double-blind Clinical Trial of Surinam Cherry Dentifrice With Anti-gingivitis Properties

Primary Purpose

Gingivitis

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Dentifrice
Sponsored by
Federal University of Paraíba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gingivitis

Eligibility Criteria

10 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged 10 to 12 years old with clinical signs of gingivitis (bleeding on probing);
  • Presence of at least 20 dental elements
  • Not using orthodontic fixed appliances
  • Susceptibility to form biofilm and gingival inflammation
  • Absence of systemic disease

Exclusion Criteria:

- Subjects who had used an antimicrobial in the last two months, including topical fluoride.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Experimental dentifrice

    Control Dentifrice

    Arm Description

    Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.

    Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%) Intervention protocol: three times per day (pea-like amount), for seven consecutive days.

    Outcomes

    Primary Outcome Measures

    Reduction in gingivitis levels
    The primary outcome of interest was the reduction in the levels of gingivitis (bleeding on probing) assessed by the Gingival Bleeding Index (GBI) proposed by Ainamo and Bay.

    Secondary Outcome Measures

    Reduction in the amount of plaque
    The secondary outcome of interest was the reduction in the amount of plaque assessed by the Simplified Oral Hygiene Index (OHI-S) described by Greene and Vermilion.

    Full Information

    First Posted
    January 5, 2016
    Last Updated
    January 5, 2016
    Sponsor
    Federal University of Paraíba
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02648139
    Brief Title
    A Randomized, Controlled, Double-blind Clinical Trial of Surinam Cherry Dentifrice With Anti-gingivitis Properties
    Official Title
    A Randomized, Controlled, Double-blind Clinical Trial of a Eugenia Uniflora Linn. (Surinam Cherry) Dentifrice With Anti-gingivitis Properties
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2008 (undefined)
    Primary Completion Date
    February 2010 (Actual)
    Study Completion Date
    November 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Federal University of Paraíba

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    In the present randomized, controlled, double-blind clinical trial, we investigated the short term clinical efficacy of a dentifrice containing Eugenia uniflora L. ripe fruit extract in preventing gingivitis in children.
    Detailed Description
    This was a randomized, controlled, double-blind clinical trial investigating the short term clinical efficacy of a dentifrice containing Eugenia uniflora L. ripe fruit extract in preventing gingivitis in children. The study consisted of a sample of 50 male and female subjects between the ages of 10 and 12 years old, who had clinical signs of gingivitis. The subjects were randomly assigned to one of two groups. The intervention group comprised 25 subjects who used the dentifrice with E. uniflora L. ripe fruit hydroalcoholic extract, three times per day, for seven consecutive days. The control group comprised 25 subjects who used the control dentifrice (fluoride, 1500 ppm and triclosan, 0.3%) for seven consecutive days. The sample size was estimated using Fleming's single-stage procedure for phase II trials. With regard to the primary outcome, a response proportion of at least 50% was defined as being clinically significant. The type I error was set as 0.05, and the type II error was set at 0.1. Based on these values, a sample size of 20 individuals per trial arm would provide 90% power (1-β) to detect any clinically relevant treatment difference of 50% or greater compared to baseline. Taking into consideration an attrition rate of approximately 20%, the final sample size per trial arm comprised 25 individuals. Clinical examinations were performed at baseline and after seven days of dentifrice use. The examination was performed by a single examiner who was adequately calibrated with a Kappa statistic of 0.8, which is considered to be satisfactory agreement according to Landis & Koch. The examination data were recorded in a specific clinical chart. The diagnosis of gingivitis (primary outcome) was assessed using the Gingival Bleeding Index (GBI) proposed by Ainamo and Bay. The accumulation of biofilm (secondary outcome) was assessed with the Simplified Oral Hygiene Index (OHI-S) described by Greene and Vermilion. Prior to the study, all of the subjects were instructed on correct tooth brushing techniques and received a kit that contained a toothbrush and one of the dentifrices (without the identification of its contents). The dentifrices were also masked with regard to flavor and color so that they could not be identified. In addition, the examiner had no knowledge of the subject allocation. Thus, the study was double-blind. The sample included only subjects who had not used an antimicrobial in the last two months, including topical fluoride.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gingivitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    50 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Experimental dentifrice
    Arm Type
    Experimental
    Arm Description
    Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
    Arm Title
    Control Dentifrice
    Arm Type
    Active Comparator
    Arm Description
    Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%) Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
    Intervention Type
    Drug
    Intervention Name(s)
    Dentifrice
    Other Intervention Name(s)
    Surrinam cherry dentifrice, Colgate total 12
    Intervention Description
    3x/day for 7 days.
    Primary Outcome Measure Information:
    Title
    Reduction in gingivitis levels
    Description
    The primary outcome of interest was the reduction in the levels of gingivitis (bleeding on probing) assessed by the Gingival Bleeding Index (GBI) proposed by Ainamo and Bay.
    Time Frame
    Baseline and seven days
    Secondary Outcome Measure Information:
    Title
    Reduction in the amount of plaque
    Description
    The secondary outcome of interest was the reduction in the amount of plaque assessed by the Simplified Oral Hygiene Index (OHI-S) described by Greene and Vermilion.
    Time Frame
    Baseline and seven days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    10 Years
    Maximum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Children aged 10 to 12 years old with clinical signs of gingivitis (bleeding on probing); Presence of at least 20 dental elements Not using orthodontic fixed appliances Susceptibility to form biofilm and gingival inflammation Absence of systemic disease Exclusion Criteria: - Subjects who had used an antimicrobial in the last two months, including topical fluoride.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ricardo D Castro, PhD
    Organizational Affiliation
    Federal University of Paraíba
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    A Randomized, Controlled, Double-blind Clinical Trial of Surinam Cherry Dentifrice With Anti-gingivitis Properties

    We'll reach out to this number within 24 hrs